Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT00140140
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸City of Hope Comprehensive Cancer Care Center, Duarte, California, United States
Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas
- Conditions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00134641
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 14
- Registration Number
- NCT00130507
- Locations
- 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 252
- Registration Number
- NCT00128310
- Locations
- 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain
🇻🇪Grupo Andino de Investigación en Oncología (GAICO), Valencia, Venezuela
S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 204
- Registration Number
- NCT00003587
- Locations
- 🇺🇸
CCOP - Montana Cancer Consortium, Billings, Montana, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
S9804: Vinorelbine in Treating Patients With Stage IV Melanoma
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2012-08-22
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 24
- Registration Number
- NCT00003828
- Locations
- 🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-11-04
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 36
- Registration Number
- NCT00004093
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 76
- Registration Number
- NCT00041067
- Locations
- 🇺🇸
Northern Rockies Radiation Oncology Center, Billings, Montana, United States
🇺🇸Great Falls Clinic, Great Falls, Montana, United States
🇺🇸Billings Clinic Cancer Center, Billings, Montana, United States
S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 95
- Registration Number
- NCT00015938
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States
Vinorelbine and XR9576 to Treat Cancer
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001944
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.